Clinicien(ne) chercheur(e)

Dr Catherine Labbé

Pneumologie

catherine.labbe@criucpq.ulaval.ca

Publications

Trier par année :

Labbé C, Leung Y, Silva Lemes JG, Stewart E, Brown C, Cosio AP, Doherty M, O'Kane GM, Patel D, Cheng N, Liang M, Gill G, Rett A, Naik H, Eng L, Mittmann N, Leighl NB, Bradbury PA, Shepherd FA, Xu W, Liu G, Howell D. Real-World EQ5D Health Utility Scores for Patients With Metastatic Lung Cancer by Molecular Alteration and Response to Therapy.. Clin Lung Cancer 2016; 0(0):.
Tomasini P, Walia P, Labbe C, Jao K, Leighl NB. Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.. Oncologist 2016; 21(12):1450-1460.
Doherty MK, Korpanty GJ, Tomasini P, Alizadeh M, Jao K, Labbé C, Mascaux CM, Martin P, Kamel-Reid S, Tsao MS, Pintilie M, Liu G, Bradbury PA, Feld R, Leighl NB, Chung C, Shepherd FA. Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer.. Radiother Oncol 2017; 123(2):195-202.
O'Kane GM, Labbé C, Doherty MK, Young K, Albaba H, Leighl NB. Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.. Oncologist 2017; 22(1):70-80.
Labbé C, Leung Y, Silva Lemes JG, Stewart E, Brown C, Cosio AP, Doherty M, O'Kane GM, Patel D, Cheng N, Liang M, Gill G, Rett A, Naik H, Eng L, Mittmann N, Leighl NB, Bradbury PA, Shepherd FA, Xu W, Liu G, Howell D. Real-World EQ5D Health Utility Scores for Patients With Metastatic Lung Cancer by Molecular Alteration and Response to Therapy.. Clin Lung Cancer 2017; 18(4):388-395.e4.
Labbé C, Cabanero M, Korpanty GJ, Tomasini P, Doherty MK, Mascaux C, Jao K, Pitcher B, Wang R, Pintilie M, Leighl NB, Feld R, Liu G, Bradbury PA, Kamel-Reid S, Tsao MS, Shepherd FA. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).. Lung Cancer 2017; 111(0):23-29.
Marcoux M, Lacasse Y, Martel S, Laberge F, Tremblay L, Gaudreau V, Raby B, Labbé C. Immunotherapy and pseudoprogression in lung adenocarcinoma. Can J Respir Crit Care Sleep Med 2017; 1(2):62.
Hubert J, Bourdages-Pageau E, Garneau CAP, Labbé C, Ugalde Figueroa PA.. Enhanced recovery pathways in thoracic surgery: the Quebec experience.. J Thorac Dis 2018; 10(4):S583-90.
Labbé C, Anderson M, Simard S, Tremblay L, Laberge F, Vaillancourt R, Lacasse Y.. Wait times for diagnosis and treatment of lung cancer: a single center experience.. Curr Oncol 2017; 24(6):367-73.
Jao K, Tomasini P, Kamel-Reid S, Korpanty GJ, Mascaux C, Sakashita S, Labbé C, Leighl NB, Liu G, Feld R, Bradbury PA, Hwang DM, Pintilie M, Tsao MS, Shepherd FA. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.. Lung Cancer 2018; 123(0):22-29.
Zer A, Sung MR, Walia P, Khoja L, Maganti M, Labbe C, Shepherd FA, Bradbury PA, Feld R, Liu G, Iazzi M, Zawisza D, Nouriany N, Leighl NB. Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer.. Clin Lung Cancer 2018; 19(5):426-434.e1.
Tomasini P, Mascaux C, Jao K, Labbe C, Kamel-Reid S, Stockley T, Hwang DM, Leighl NB, Liu G, Bradbury PA, Pintilie M, Tsao MS, Shepherd FA.. Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.. Clin Lung Cancer 2019; 20(3):e338-e345.
Clemenceau A, Gaudreault N, Henry C, Ugalde Figueroa PA, Labbé C, Laviolette M, Joubert P, Bossé Y. Tumor-based gene expression biomarkers to predict survival following curative intent resection for stage I lung adenocarcinoma.. PLoS One 2018; 13(11):e0207513.
Juergens RA, Mariano C, Jolivet J, Finn N, Rothenstein J, Reaume MN, Faghih A, Labbé C, Owen S, Shepherd FA, Villeneuve J, Romeyer F, Pettersson F, Butts C.. Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort.. Curr Oncol 2018; 25(6):384-392.
O'Kane GM, Su J, Tse BC, Tam V, Tse T, Lu L, Borean M, Tam E, Labbé C, Naik H, Mittmann N, Doherty MK, Bradbury PA, Leighl NB, Shepherd FA, Richard NM, Edelstein K, Shultz D, Brown MC, Xu W, Howell D, Liu G.. The Impact of Brain Metastases and Associated Neurocognitive Aspects on Health Utility Scores in EGFR Mutated and ALK Rearranged NSCLC: A Real World Evidence Analysis.. Oncologist 2019; 24(7):e501-e509.
Jiang SX, Walton RN, Hueniken K, Baek J, McCartney A, Labbé C, Smith E, Chan SWS, Chen R, Brown C, Patel D, Liang M, Eng L, Sacher A, Bradbury P, Leighl NB, Shepherd FA, Xu W, Liu G, Hurry M, O'Kane GM. Real-world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non-small cell lung cancer.. Cancer Med 2019; 8(18):7542-7555.
Fiset PO, Labbé C, Young K, Craddock KJ, Smith AC, Tanguay J, Pintilie M, Wang R, Torlakovic E, Cheung C, da Cunha Santos G, Ko HM, Boerner SL, Hwang DM, Leighl NB, Tsao MS. Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population-based reflex testing.. Cancer 2019; 125(22):4043-4051.
Elkrief A, Richard C, Malo J, Cvetkovic L, Florescu M, Blais N, Tehfe M, Messaoudene M, Gagné A, Orain M, Medjebar S, Wan-Chow-Wah D, Joubert P, Labbé C, Ghiringhelli F, Routy B. Efficacy of immune checkpoint inhibitors in older patients with non-small cell lung cancer: Real-world data from multicentric cohorts in Canada and France.. J Geriatr Oncol 2020; 11(5):802-806.
Sung M, Zer A, Walia P, Khoja L, Maganti M, Labbe C, Shepherd FA, Bradbury PA, Liu G, Leighl NB. Correlation of immune-related adverse events and response from immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.. J Thorac Dis 2020; 12(5):2706-2712.
Denault MH, Morin-Thibault LV, Kermelly SB, Labbé C. Prevention and Treatment of Thromboembolic Events in Patients with Cancer: Advances and Challenges.. Am J Respir Crit Care Med 2020; 202(1):124-127.
Bouchard N, Labbé C.. Limmunothérapie dans le traitement du cancer du poumon. Pneumonite et autres effets secondaires.. Info-RQESR 2020; 0(0):Epub.
Dubé-Pelletier M, Labbé C. Routine Neuroimaging in Patients with Stage IV Non-Small Cell Lung Cancer: A Single Center Experience.. Curr Oncol 2021; 28(2):1125-1136.
Valette K, Li Z, Bon-Baret V, Chignon A, Bérubé JC, Eslami A, Lamothe J, Gaudreault N, Joubert P, Obeidat M, van den Berge M, Timens W, Sin DD, Nickle DC, Hao K, Labbé C, Godbout K, Côté A, Laviolette M, Boulet LP, Mathieu P, Thériault S, Bossé Y. Prioritization of candidate causal genes for asthma in susceptibility loci derived from UK Biobank.. Commun Biol 2021; 4(1):700.
Debieuvre D, Juergens RA, Asselain B, Audigier-Valette C, Auliac JB, Barlesi F, Benoit N, Bombaron P, Butts CA, Dixmier A, Gröschel A, Gutz S, Labbé C, Moro-Sibilot D, Pérol M, Raspaud C, Schumann C, Juarez-Garcia A, Lakhdari K, Pettersson F, Penrod JR, Reynaud D, Waldenberger D, Allan V, Sebastian M. Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada.. Lung Cancer 2021; 157(0):40-47.
Mai V, Quigley N, Roy P, Labbé C. Novelties in Lung Cancer Screening.. Am J Respir Crit Care Med 2021; 204(5):596-598.
Mai V, Trahan S, Pagé S, Simon M, Labbé C.. Severe hyponatremia due to paraneoplastic syndrome of inappropriate antidiuretic hormone secretion in non-small cell lung carcinoma transforming to small cell lung carcinoma during treatment with immune checkpoint inhibitor.. Curr Probl Cancer Case Rep 2021; 4(0):100125.
Rouabhia D, Audet R, Desmeules P, Labbé C.. Stage IV ALK-positive lung adenocarcinoma: 7.5-year complete remission with crizotinib.. Ann Hematol Oncol 2021; 8(6):1350.
Beaudet MÉ, Lacasse Y, Labbé C. Palliative Systemic Therapy Given near the End of Life for Metastatic Non-Small Cell Lung Cancer.. Curr Oncol 2022; 29(3):1316-1325.
Denault MH, Labbé C, St-Pierre C, Fournier B, Gagné A, Morillon C, Joubert P, Simard S, Martel S. Wait Times and Survival in Lung Cancer Patients across the Province of Quebec, Canada.. Curr Oncol 2022; 29(5):3187-3199.
Ruel LJ, Li Z, Gaudreault N, Henry C, Saavedra Armero V, Boudreau DK, Zhang T, Landi MT, Labbé C, Couture C, Desmeules P, Joubert P, Bossé Y. Tumor Mutational Burden by Whole-Genome Sequencing in Resected NSCLC of Never Smokers.. Cancer Epidemiol Biomarkers Prev 2022; 31(12):2219-2227.
Roy V, Ugalde PA, Bourdages-Pageau E, Lacasse Y, Labbé C. Transthoracic needle biopsy versus surgical diagnosis for solid pulmonary nodules.. J Thorac Dis 2022; 14(7):2472-2480.
Desmeules P, Dusselier M, Bouffard C, Bafaro J, Fortin M, Labbé C, Joubert P. Retrospective Assessment of Complementary Liquid Biopsy on Tissue Single-Gene Testing for Tumor Genotyping in Advanced NSCLC.. Curr Oncol 2023; 30(1):575-585.
Dubé-Pelletier M, Labbé C, Côté J, Pelletier-St-Pierre AA. Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung Cancer.. Oncologist 2023; 0(0):Epub.

Dr Catherine Labbé

Publications

Support tomorrow's medicine, now.